会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • OCULAR THERAPY USING ALPHA-2 ADRENERGIC RECEPTOR AGONISTS HAVING ENHANCED ANTERIOR CLEARANCE RATES
    • 使用具有增强的前列腺增生率的ALPHA-2 ADRENERGIC受体激动剂进行的OCULAR治疗
    • WO2006122165A3
    • 2007-05-31
    • PCT/US2006018019
    • 2006-05-09
    • ALLERGAN INCHUGHES PATRIC MBURKE JAMES ACHANG-LIN JOAN-EN
    • HUGHES PATRIC MBURKE JAMES ACHANG-LIN JOAN-EN
    • A61K9/00
    • A61K9/0051A61K9/0048A61K9/1647
    • Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual's eye to which the material is administered. The alpha 2 adrenergic receptor agonist may have a vitreal half-life greater than about three hours. The present materials are effective in treating an ocular condition(s) that affect the anterior segment of an eye, or the anterior and posterior segment of the eye. The materials are suitable for intravitreal or periocular administration and can provide prolonged drug delivery and therapeutic benefits to patients to which the materials have been administered. The alpha 2 adrenergic receptor agonists can be provided in liquid-containing formulations and/or bioerodible and/or non-bioerodible polymeric implants and microparticles. Methods of making and using the present materials are also described.
    • 眼科治疗材料,例如含液组合物和聚合物药物递送系统,包括治疗成分,其包括α2肾上腺素能受体激动剂,其从施用该物质的个体眼睛的前段清除。 α2肾上腺素能受体激动剂可具有大于约3小时的玻璃体半衰期。 本发明的材料可有效治疗影响眼前段或眼部前段和后段的眼睛状况。 这些材料适用于玻璃体内或眼周内给药,并且可以为已经施用材料的患者提供延长的药物递送和治疗益处。 α2肾上腺素能受体激动剂可以在含液制剂和/或生物可侵蚀和/或非生物可侵蚀的聚合物植入物和微粒中提供。 还描述了制备和使用本发明材料的方法。
    • 8. 发明申请
    • OCULAR THERAPY USING ALPHA-2 ADRENERGIC RECEPTOR AGONISTS HAVING ENHANCED ANTERIOR CLEARANCE RATES
    • 使用具有增强的前列腺增生率的ALPHA-2 ADRENERGIC受体激动剂进行的OCULAR治疗
    • WO2006122165A2
    • 2006-11-16
    • PCT/US2006/018019
    • 2006-05-09
    • ALLERGAN, INC.HUGHES, Patric, M.BURKE, James, A.CHANG-LIN, Joan-En
    • HUGHES, Patric, M.BURKE, James, A.CHANG-LIN, Joan-En
    • A61K9/0051A61K9/0048A61K9/1647
    • Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual's eye to which the material is administered. The alpha 2 adrenergic receptor agonist may have a vitreal half-life greater than about three hours. The present materials are effective in treating an ocular condition(s) that affect the anterior segment of an eye, or the anterior and posterior segment of the eye. The materials are suitable for intravitreal or periocular administration and can provide prolonged drug delivery and therapeutic benefits to patients to which the materials have been administered. The alpha 2 adrenergic receptor agonists can be provided in liquid-containing formulations and/or bioerodible and/or non-bioerodible polymeric implants and microparticles. Methods of making and using the present materials are also described.
    • 眼科治疗材料,例如含液组合物和聚合物药物递送系统,包括治疗成分,其包括α2肾上腺素能受体激动剂,其从施用该物质的个体眼睛的前段清除。 α2肾上腺素能受体激动剂可具有大于约3小时的玻璃体半衰期。 本发明的材料可有效治疗影响眼前段或眼部前段和后段的眼睛状况。 这些材料适用于玻璃体内或眼周内给药,并且可以为已经施用材料的患者提供延长的药物递送和治疗益处。 α2肾上腺素能受体激动剂可以在含液制剂和/或生物可侵蚀和/或非生物可侵蚀的聚合物植入物和微粒中提供。 还描述了制备和使用本发明材料的方法。
    • 9. 发明申请
    • OPHTHALMIC COMPOSITIONS COMPRISING dDC
    • 包含dDC的透明组合物
    • WO2006104760A2
    • 2006-10-05
    • PCT/US2006010176
    • 2006-03-21
    • ALLERGAN INCHUGHES PATRICK MSCHIFFMAN RHETT MJENSEN HAROLD GCHANG-LIN JOAN-EN
    • HUGHES PATRICK MSCHIFFMAN RHETT MJENSEN HAROLD GCHANG-LIN JOAN-EN
    • A61K9/0048A61K31/7068
    • A composition comprising dDC and a polymer, wherein the composition is an aqueous liquid with a viscosity which increases upon contact with a surface of an eye is disclosed herein. An aqueous composition comprising a therapeutically effective concentration of dDC, wherein the concentration of dDC is less than 1% is also disclosed. An eye drop comprising a therapeutically effective amount of dDC, wherein the amount of dDC is less than 300 µg is also disclosed. A method comprising administering an effective amount of dDC topically to an eye of a person suffering from viral conjunctivitis a viral infection, wherein less than 300 µL of dDC is administered to said eye is also disclosed. A kit comprising a composition and a dispenser, wherein said dispenser dispenses a drop comprising a therapeutically effective amount of dDC, wherein the amount of dDC is less than 300 µg is also disclosed.
    • 包含dDC和聚合物的组合物,其中所述组合物是具有在与眼表面接触时增加的粘度的水性液体。 还公开了包含治疗有效浓度的dDC的水性组合物,其中dDC的浓度小于1%。 还公开了包含治疗有效量的dDC的滴眼剂,其中dDC的量小于300μg。 还公开了一种将有效量的dDC局部施用于患有病毒性结膜炎的人的眼睛的病毒感染的方法,其中向所述眼睛施用小于300μL的dDC。 一种包含组合物和分配器的试剂盒,其中所述分配器分配包含治疗有效量的dDC的液滴,其中dDC的量小于300μg也被公开。